MALMÖ, Sweden--(BUSINESS WIRE)--Regulatory News: Hansa Medical AB (publ) (STO:HMED) today announced that the company sponsored pivotal multicenter study in the US with IdeS in refractory highly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback